Publications for William E. Dager

College of Pharmacy (TUC)
  • Dager, W. E., & Banares, L. (2017). Reversing the anticoagulation effects of dabigatran. Hospital Practice, 45(2), 29-38. This material can be found here.

  • Maker, J. H., & Dager, W. E. (2017). Acute kidney injury. In J. T. DiPiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, & L. M. Posey (Eds.), Pharmacotherapy: A pathophysiologic approach (pp. 589-608). New York, NY: McGraw-Hill Education.

  • Chen, L. D., Roberts, A. J., & Dager, W. E. (2016). Safety and efficacy of starting warfarin after two consecutive platelet count rises in heparin-induced thrombocytopenia. Thrombosis Research, 144, 229-233. doi:10.1016/j.thromres.2016.05.023

  • Dager, W. E., & Hellwig, T. (2016). Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants [Supplemental material]. American Journal of Health-System Pharmacy, 73(10 Suppl. 2), S14-S26. doi:10.2146/ajhp150960

  • Dager, W. E., & Roberts, A. J. (2016). Prevention and treatment of venous thromboembolism. In B. L. Erstad (Ed.), Critical care pharmacotherapy (pp. 449-467). Lenexa, KS: American College of Clinical Pharmacy.

  • Dager, W. E., & Halilovic, J. (2014). Acute kidney injury. In J. T. DiPiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, & L. M. Posey (Eds.), Pharmacotherapy: A pathophysiologic approach (9th ed., pp. 611-632). New York, NY: McGraw-Hill Medical.

  • Pon, T. K., Dager, W. E., Roberts, A. J., & White, R. H. (2014). Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients. Thrombosis Research, 133(6), 1023-1028. doi:10.1016/j.thromres.2014.03.036

  • Ragucci, K. R., O'Bryant, C. L., Campbell, K. B., Buck, M. L., Dager, W. E., Donovan, J. L., . . . Prohaska, E. (2014). The need for PGY2-trained clinical pharmacy specialists. Pharmacotherapy, 34(6), e65-e73. doi:10.1002/phar.1430

  • Chang, D. N., Dager, W. E., & Chin, A. I. (2013). Removal of dabigatran by hemodialysis. American Journal of Kidney Diseases, 61(3), 487-489.  doi:10.1053/j.ajkd.2012.08.047

  • Dager, W. E. (2013). Developing a management plan for oral anticoagulant reversal. American Journal of Health-System Pharmacy, 70(10), S21-S31. This material can be found here.

  • Dager, W. E., Gosselin, R. C., & Roberts, A. J. (2013). Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Critical Care Medicine, 41(5), e42-e46. doi:10.1097/CCM.0b013e31827caaa3

  • Gosselin, R. C., Dwyre, D. M., & Dager, W. E. (2013). Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Annals of Pharmacotherapy, 47(12), 1635-1640. doi:10.1177/1060028013509074

  • Nagle, E. L., Dager, W. E., Duby, J. J., Roberts, A. J., Kenny, L. E., Murthy, M. S., & Pretzlaff, R. K. (2013). Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatric Critical Care Medicine, 14(4), e182-188. doi:10.1097/PCC.0b013e31827200b6.

  • Nutescu, E. A., Dager, W. E., Kalus, J. S., Lewin III, J. J., & Cipolle, M. D. (2013). Management of bleeding and reversal strategies for oral anticoagulants: Clinical practice considerations. American Journal of Health-System Pharmacy, 70(21), 1914-1929. This material can be found here.

  • Roberts, A. J., Sutter, M. E., & Dager, W. E. (2013). Reversal of novel anticoagulants: Role of clotting factors and complex concentrates. Current Emergency and Hospital Medicine Reports, 1(4), 200-207. doi:10.1007/s40138-013-0026-2

  • Smythe, M. A., Fanikos, J., Gulseth, M. P., Wittkowsky, A. K., Spinler, S. A., Dager, W. E., & Nutsecu, E. A. (2013). Rivaroxaban: Practical considerations for ensuring safety and efficacy. Pharmacotherapy, 33(11), 1223-1245. doi:10.1002/phar.1289

  • Tsu, L. V., & Dager, W. E. (2013). Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes. Annals of Pharmacotherapy, 47(4), 573-577. doi:10.1345/aph.1R576

  • Dager, W. E. (2012). Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: Exploring the evidence, guidelines, and challenges remaining. The Annals of Pharmacotherapy, 46(1), 79-88. doi:10.1345/aph.1P626

  • Dager, W. E., Gosselin, R. C., Kitchen, S., & Dwyre, D. (2012). Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: A multicenter, in vitro study. The Annals of Pharmacotherapy, 46(12), 1627-1636.  doi:10.1345/aph.1R179 

  • Tsu, L. V., & Dager, W. E. (2012). Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia. Pharmacotherapy, 32(1), 20-26. doi:10.1002/PHAR.1016

  • Tsu, L. V., Dienes, J. E., & Dager, W. E. (2012). Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting. The Annals of Pharmacotherapy, 46(12), 1617-1626. doi:10.1345/aph.1R497

  • Dager, W. E. (2010). Issues in assessing and reducing the risk for venous thromboembolism. American Journal of Health-System Pharmacy, 67(10 Suppl. 6), S9-16. doi:10.2146/ajhp100177

  • Dager, W. E., & Kiser, T. H. (2010). Systemic anticoagulation considerations in chronic kidney disease. Advances in Chronic Kidney Disease, 17(5), 420-427. doi:10.1053/j.ackd.2010.06.002

  • Dager, W. E., Gulseth, M. P., & Nutescu, E. A. (2010). Anticoagulation therapy: A point of care guide. Bethesda, MD: American Society of Health-System Pharmacists.

  • Dager, W. E., Shulman, R., & Jacobi, J. (2010). Preparation and training of critical care pharmacists. In H. Flaatten, R. P. Moreno, C. Putensen, & A. Rhodes, (Eds.), Organisation and management of intensive care (pp. 133-142). Berlin, Germany: Medical Scientific Publishing GmbH & Co. This material can be found here.

First Prev 1 2 Next Last